MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyaf260

Медицинская библиотека · The oncologist · 2025

Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.

Wolff Louis, Ertl Carolin, Heinzerling Lucie, Aspeslagh Sandrine, Verhaert Marthe, Lattenist Raphael, Confente Caterina, Lambert Catherine, Ilzkovitz Maxime

СтатьяКлинический случайПеревод пока не подготовлен

Аннотация

BACKGROUND

Acquired hemophilia A (AHA) is a rare but potentially life-threatening autoimmune bleeding disorder and immune-related adverse event (irAE) associated with immune checkpoint inhibitors (ICI). This study discusses 3 new cases of ICI-induced AHA from Belgium and the SERIO-Side Effect Registry Immuno-Oncology (www.serio-registry.org), placing them in the context of existing literature.

METHODS

One case was encountered at a tertiary care center in Belgium. SERIO was queried and yielded another 2 cases. A comprehensive literature review using PubMed identified 8 additional cases.

RESULTS

A total of 11 patients were analyzed, with a median age of 68 years (range: 56-71), 10 were male. Most (9/11) were treated with anti-PD-1 monotherapy. In 5 cases, toxicity appeared before the fourth cycle. Immunosuppressive therapy successfully achieved complete resolution of AHA in 9 of 11 patients. For the first time, one patient was successfully treated with emicizumab, a monoclonal bispecific antibody, which bridges activated factor IX and factor X.

CONCLUSIONS

Clinicians should be vigilant about ICI-induced AHA as a potentially severe irAE. Prolonged aPTT requires thorough evaluation. Upon AHA confirmation, eradication of anti-FVIII antibodies with corticosteroids, rituximab, or other immunosuppressant should be attempted. Emicizumab offers advantages over traditional replacement therapy, including ease of use and a potential reduction in immunosuppressive drug requirements-an important consideration in ICI-treated patients. Further research is needed to fully understand the pathophysiology and optimize treatment strategy for AHA.

Для цитирования: Wolff Louis, Ertl Carolin, Heinzerling Lucie, Aspeslagh Sandrine, Verhaert Marthe, Lattenist Raphael, Confente Caterina, Lambert Catherine, Ilzkovitz Maxime. Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.. The oncologist. 2025. DOI: 10.1093/oncolo/oyaf260.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.